Cantor analyst Daniel Brims was out pounding the table on Threshold Pharmaceuticals, Inc. (NASDAQ:THLD) Thursday, reiterating a Buy rating and price target of $14, which implies an upside of 258.5% from current levels.
Brims noted, “We believe read-out of top-line OS data in the two pivotal phase 3 trials of evofosfamide in pancreatic cancer and STS, which are expected in early 2016, will be the key catalysts for THLD and enable both FDA and EMA regulatory submissions shortly thereafter. We also believe proof-of-concept phase 2 trials of TH-4000 in both NSCLC as well as head and neck cancers will initiate in mid:15, and interim data will potentially be presented in 2016 at scientific conferences and allow us to begin assigning value to this asset.”
According to TipRanks.com, which measures analysts’ and bloggers’ success rate based on how their calls perform, analyst Daniel Brims has a total average return of 2.7% and a 45.9% success rate. Brims has a -0.2% average return when recommending THLD, and is ranked #1744 out of 3688 analysts.
All the 7 analysts polled by TipRanks rate Threshold Pharmaceuticals stock a Buy. With a return potential of 260%, the stock’s consensus target price stands at $14.10.